Suzhou Motif Biotech Co., Ltd. is located in the Suzhou High-Tech Zone (Huqiu District) as an innovative bioscience firm dedicated to the research, development, and production of peptide-related products. Founded in 2021, Motif Biotech launched its research and manufacturing operations in March 2023.

Driven by peptide technology, Motif Biotech is dedicated to leading the CRDMO industry by integrating peptide research, process development, and API production.

In 2024, Motif Biotech has invested approximately 100 million yuan in research and development (R&D), operating over 100 R&D laboratories  across 4,300 square meters with an annual peptide production target of 30 kilograms. The company has also established a GMP-compliant workshop spanning 800 square meters, rigorously adhering to ICHQ7 guidelines. Its production and quality standards for peptide drugs fully comply with FDA, EMA, and NMPA regulations.

With decades of expertise in peptide synthesis, Motif Biotech is capable of producing over 95% of the peptide drugs available on the market. This is driven through a comprehensive process, starting from peptide drug design and screening to modification and optimization. The company’s CRO and CDMO divisions deliver high-quality and efficient services at competitive prices.

Motif Biotech’s integrated CRDMO (CRO/CDMO) platform provides fully customizable services for peptide drugs, covering every stage from early drug discovery to preclinical research and clinical trial sample production. By using advanced solid-phase, liquid-phase, and hybrid synthesis techniques, the company produces bioactive peptides tailored for diverse applications and specifications. Motif Biotech is committed to efficiently delivering exceptional peptide R&D solutions worldwide.

Guided by the core values of "Successful customers, successful employees, successful company," Motif Biotech is set to exceed 100 kilograms of annual production capacity by 2025. With ambitions to expand its industrial CRDMO reach, the company is leveraging cutting-edge peptide technology licenses for peptide-drug conjugates (PDC), antibody-drug conjugates (ADC), and nucleic acid-drug conjugates. These efforts further solidify Motif Biotech’s position as a global leader in the peptide CRDMO landscape.